Antagonists of interleukin-2 receptor
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsKenan Christopher Garcia, Aron Levin, Aaron Ring
Life of this patent
Estimating the term…
Abstract
Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
Claims18
An interleukin-2 receptor β (IL-2Rβ) binding protein, wherein the equilibrium dissociation constant for the IL-2Rβ of said binding protein is less than that of wild-type human IL-2 (hIL-2), and wherein said IL-2Rβ binding protein comprises the following amino acid substitutions:
- L80F, R81D, L85V, I86V, and I92F, numbered in accordance with wild-type hIL-2.
Dependencies are inferred from the claim text.